Metastatic Renal Cell CarcinomaФаза 2NCT07123090
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Sasanlimab, Palbociclib, Axitinib
38 Phase 2 studies recruiting right now, most recently updated first.
Open the Phase 2 page · a list of only those studies
Triangle is made by Triangle Health, Inc.
Kidney and bladder38 studies
Metastatic Renal Cell CarcinomaФаза 2NCT07123090
Sasanlimab, Palbociclib, Axitinib
IvonescimabФаза 2NCT06940518
Ivonescimab
Advanced Clear Cell Renal Cell CarcinomaФаза 2NCT05361720
Cabozantinib, Ipilimumab, Nivolumab
Nonmuscle-invasive Bladder CancerФаза 2NCT06971614
T3011
Adenocarcinoma of the BladderФаза 2NCT06041503Papers
Pembrolizumab, Enfortumab vedotin
Bladder CancerФаза 2NCT07762586
Neoadjuvant Therapy, Upfront radical cystectomy
Muscle-Invasive Bladder CarcinomaФаза 2NCT06417190
Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)
Metastatic Renal Cell CarcinomaФаза 2NCT05263050
Cabozantinib, Nivolumab
Clear Cell Renal Cell Cancer (ccRCC)Фаза 2NCT07043608
Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT), Bone Scan
Urothelial CarcinomaФаза 2NCT04879329
disitamab vedotin, pembrolizumab
Oligometastatic Renal Cell CarcinomaФаза 2NCT06004336
Pembrolizumab, Radiation therapy
Renal Pelvis and Ureter Urothelial CarcinomaФаза 2NCT05775471
Biopsy, Biospecimen Collection, Enfortumab Vedotin, MR Urography
Small Cell Neuroendocrine Carcinoma of BladderФаза 2NCT05312671
Atezolizumab, Carboplatin, Cisplatin, Etoposide
Metastatic Bladder Urothelial CarcinomaФаза 2NCT06630416
Biospecimen Collection, Computed Tomography, Pemetrexed